Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMELSIU)

Drug Name
MIP-1095 Drug Info
Synonyms
MIP-1095; 949575-22-8; CHEMBL456029; 754M4I9737; L-Glutamic acid, N-((((1S)-1-carboxy-5-((((4-iodophenyl)amino)carbonyl)amino)pentyl)amino)carbonyl)-; SCHEMBL11930755; (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid; UNII-754M4I9737; BDBM50265783; AKOS040746114; (s)-2-(3-((s)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido) pentanedioic acid; (S)-2-(3-((S)-1-Carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioicacid; (2S)-2-[[(1S)-1-carboxy-5-[(4-iodophenyl)carbamoylamino]pentyl]carbamoylamino]pentanedioic acid
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 1 [1]
Cross-matching ID
PubChem CID
24957011
TTD Drug ID
DMELSIU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glutamate carboxypeptidase II (GCPII)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Capromab DMHERIJ Prostate cancer 2C82.0 Approved [3]
PSMA-11 Ga-68 DMWLTU2 Diagnostic imaging N.A. Approved [4]
Lutetium Lu-177 vipivotide tetraxetan DMQ0IZ6 Prostate cancer 2C82.0 Approved [5]
177-Lu-PSMA-617 DMX178V Prostate cancer 2C82.0 Phase 3 [6]
BAY 2315497 DMUHH2G Prostate cancer 2C82.0 Phase 3 [7]
J 591 Lu-177 DM9XKJU Prostate cancer 2C82.0 Phase 2 [8]
G-202 DMQR9I8 Adenocarcinoma 2D40 Phase 2 [9]
ATL101 DMYAQV2 Influenza virus infection 1E30-1E32 Phase 2 [10]
99mTc-MIP-1404 DML4GU1 Prostate cancer 2C82.0 Phase 2 [11]
MLN-591RL DMJHVZC Prostate cancer 2C82.0 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate carboxypeptidase II (GCPII) TT9G4N0 FOLH1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03030885) A Phase 1, Open-Label, Dose Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S.National Institutes of Health.
2 Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92.
3 Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
6 Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
7 ClinicalTrials.gov (NCT03724747) Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
8 Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
9 National Cancer Institute Drug Dictionary (drug id 666090).
10 Clinical pipeline report, company report or official report of Atlab pharma.
11 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
12 Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.